000 03970nam a22004815i 4500
001 vtls000541276
003 RU-ToGU
005 20210922081855.0
007 cr nn 008mamaa
008 160915s2014 xxu| s |||| 0|eng d
020 _a9781461495604
_9978-1-4614-9560-4
024 7 _a10.1007/978-1-4614-9560-4
_2doi
035 _ato000541276
040 _aSpringer
_cSpringer
_dRU-ToGU
050 4 _aRB45
072 7 _aMJF
_2bicssc
072 7 _aMED038000
_2bisacsh
082 0 4 _a616.15
_223
245 1 4 _aThe Coagulation Consult
_helectronic resource
_bA Case-Based Guide /
_cedited by Alan Lichtin, John Bartholomew.
260 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2014.
300 _aXII, 279 p. 46 illus., 38 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
505 0 _aLaboratory Analysis of Coagulation -- Easy Bruisability -- Prolonged PT -- Prolonged PTT -- Prolongation of Both PT and aPTT -- Excessive Bleeding with Normal Prothrombin Time, Partial Thromboplastin Time, and Platelet Count -- Diagnosing Thrombocytopenia in the Clinic -- Thrombocytopenia in the Intensive Care Unit and after Solid Organ Transplantation -- Thrombocytosis -- Prolonged Bleeding after Surgery -- The Excessively Clotting Cancer Patient -- Thrombotic Risk factors -- Clotting around Catheters and Other Devices -- Heparin-Induced Thrombocytopenia -- Surgery on Patients on Antiplatelet Agents -- Newer Oral Anticoagulants -- Pregnancy.
520 _aThere have been many changes in the field of coagulation during the past decade. New concepts of epidemiology of risk factors for thrombosis now help clinicians predict who is more likely to form clots after surgery, or after being placed on oral contraceptives. New anticoagulants have the potential to redefine how patients with atrial fibrillation and venous thrombosis are managed. There are new forms of recombinant clotting factors which have changed our approach to hypofibrinogenemia and von Willebrand’s disease. Newer antiplatelet agents are available and their use in patients receiving cardiac stents has mushroomed. The management of thrombosis in the setting of pregnancy has changed over the past decade, as well as the way clinicians approach women with multiple miscarriages. An entire new class of compounds, the thrombopoietins, are available to treat individuals with immune thrombocytopenic purpura (ITP). The Coagulation Consult covers major topics of interest to hematologists who are asked to consult on individuals with coagulation related diseases, and encompasses the field’s most recent developments. This “case-directed” book describes state-of-the-art approaches to patients with bleeding and clotting disorders, as well as laboratory tests for coagulation. Chapters include different vignettes, focus on typical clinical consult questions, and lay out specific types of treatment. Practicing clinicians being confronted with a coagulation consult, students, residents, fellows and attending physicians will find this unique text an invaluable resource for some of the newer areas of coagulation science, therapy and pharmacology.
650 0 _amedicine.
_9566220
650 0 _aInternal medicine.
_9566286
650 0 _aHematology.
_9307898
650 0 _aOncology.
_9303086
650 1 4 _aMedicine & Public Health.
_9566221
650 2 4 _aHematology.
_9307898
650 2 4 _aOncology.
_9303086
650 2 4 _aInternal Medicine.
_9566287
700 1 _aLichtin, Alan.
_eeditor.
_9445642
700 1 _aBartholomew, John.
_eeditor.
_9445643
710 2 _aSpringerLink (Online service)
_9143950
773 0 _tSpringer eBooks
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4614-9560-4
912 _aZDB-2-SME
999 _c398587